OSR (OSRH) subsidiary Vaximm said Wednesday that final data from a phase 2a trial showed that its investigational vaccine VXM01 in combination with avelumab "could offer meaningful clinical benefit" in patients with recurrent glioblastoma, a type of aggressive brain cancer.

The 25-patient trial also showed that the VXM01-avelumab combination therapy was well-tolerated and in line with previously reported data on avelumab alone, the company said.

The non-resected patient cohort showed a 12.0% objective response rate, while 12.0% of these patients showed a partial remission and 4.0% had stable disease, the company said.

The oral immunotherapy is designed to activate T-cells to attack tumor vasculature and cancer cells directly, the company said.

OSR shares climbed by nearly 130% in premarket trading.